Senior consultant Urooncology & Robotics SUO fellow, uro-oncology, UTHealth San Antonio, MaysCancer Centre, AIIMS Delhi alumni-medical school and residency
San Antonio, TX
Joined August 2011
- Tweets179
- Following470
- Followers416
- Likes97
Excited to host UroOncology Conclave 2026 at @HospitalsApollo .live operative robotic partial Nx, hands on simulation for residents/fellows ..eager to listen @DharamKaushik5 on complex kidney cancer surgeries …
Looking forward to this great discussion at UAA2026
Meet Leading Urologists and Explore Digital Innovation with REDPINE at UAA 2026!
#REDPINE #UAA2026 #Urology #Endourology #PCNL #RIRS #ECIRS #DigitalSurgery #MedicalInnovation #MedicalMeeting
Join us today in ISU/USI-MAP program on understanding nuances of PROTEUS RCT...for young residents ... @VattikutiRobotx @usioffice @EAUYAUrology @YouthUSI @SocietySURS @NEJM @IauaSociety @AmerUrological ..The webinar link
:us02web.zoom.us/j/8447396564…
Robotic surgery is a boon..in simple terms explained …thank you for over 1.4million views @socroboticsurg @VattikutiRobotx @usioffice @IndianJUrology @SIU_urology
instagram.com/reel/DalCcKGJh…
Robotic surgery explained in simple terms
instagram.com/reel/DalCcKGJh…
Grateful to @usioffice for an amazing webinar on "Smart presentation to smart tools'.. more than 190 participants.. super enthusiastic delegates and so much fun!!!...stay tuned for some more powerful sessions
Harshit Garg MCh MBBS MD retweeted
Excited to convene AI workshop with ISU-USI @usioffice @nzusioffice @IndianJUrology ..smart presentations using AI tools is the way forward and lets discuss that... @suryaprakashuro @lkeshav1965 ..
pls join us at
elearning.usi.org.in/login
Excited to convene AI workshop with ISU-USI @usioffice @nzusioffice @IndianJUrology ..smart presentations using AI tools is the way forward and lets discuss that... @suryaprakashuro @lkeshav1965 ..
pls join us at
elearning.usi.org.in/login
Harshit Garg MCh MBBS MD retweeted
Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ
Happy to share I was invited to host a workshop on ‘Smart AI tools for smart research’ at NCAIHC held at BHu..housefull workshop…we all enjoyed and learnt so many things together…thanks for opportunity @BenarasNews @MaxHealthcare
An excellent editorial remark…the BCG naive NMIBC management is truly evolving but still there is so much to do…@MaxKates @noelonika @SvatekRob
Our take on the evolving landscape of BCG naive NMIBC. @brady_urology
kwnsfk27.r.eu-west-1.awstrac…
Sequencing systemic therapy in mRCC after first line therapy…a very intense topic made so simple and covered so comprehensively by none other than @montypal at @aiims_newdelhi …with @neerajaiims @PGrivasMDPhD @shilpaonc @batraatulonc @brusabhanu1 …#uroonc
Ev/pembro is a true game changer in all aspects of bladder cancer …@brusabhanu1 @AnshulGupt19470 @shilpaonc @rajeevkumar
KEYNOTE-B15/ EV-304 demonstrates a statistically significant and clinically meaningful benefit in all three key hypotheses of EFS, OS, and pCR rates for perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy for cisplatin-eligible patients with MIBC - Merck.com @shilpaonc @PGrivasMDPhD @IBCG_BladderCA @tompowles1 @neerajaiims @AndreaNecchi @OAlhalabiMD
Harshit Garg MCh MBBS MD retweeted
KEYNOTE-B15/ EV-304 demonstrates a statistically significant and clinically meaningful benefit in all three key hypotheses of EFS, OS, and pCR rates for perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant chemotherapy for cisplatin-eligible patients with MIBC - Merck.com @shilpaonc @PGrivasMDPhD @IBCG_BladderCA @tompowles1 @neerajaiims @AndreaNecchi @OAlhalabiMD
Speaking on artificial intelligence and its ever evolving role at #siu2025 @Cacciamani_MD @kinjutweets @abhisingh82 @RajeevTPuro …